Precigen(PGEN) - 2025 Q4 - Annual Results

Exhibit 99.1 Precigen Reports Full Year 2025 Financial Results and Business Updates bill government and commercial insurers for physician-administered therapies. Assignment of a permanent J-code streamlines claims processing and will likely facilitate broader patient access. PRGN-2009 AdenoVerse Immunotherapy in HPV-associated cancers GERMANTOWN, MD, March 25, 2026 – Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines ...